Evidence map›Paper›PMID 40884299›Full record

ArticleJAMA cardiology2025

Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region.

Kouamivi Mawuenyegan Agboyibor, Aboubakari Nambiema, Fifonsi Gbeasor, Noël Barengo, Joseph Chukwudi Okeibunor, Xavier Jouven, Jean-Marie Dangou, Farshad Farzadfar, Jean-Philippe Empana

Abstract read
In one paragraph

Article in JAMA cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Kouamivi Mawuenyegan AgboyiborUniversité Paris Cité, Inserm, Department of Epidemiology, Paris Cardiovascular Research Center, Paris, France.
Aboubakari NambiemaUniversité Paris Cité, Inserm, Department of Epidemiology, Paris Cardiovascular Research Center, Paris, France.
Fifonsi GbeasorDepartment of Public Health, Université de Lomé, Lomé, Togo.
Noël BarengoDivision of Medical and Population Health Sciences Education and Research, Florida International University, Herbert Wertheim College of Medicine, Miami.
Joseph Chukwudi OkeibunorWorld Health Organization Regional Office for Africa, Brazzaville, Congo.
Xavier JouvenUniversité Paris Cité, Inserm, Department of Epidemiology, Paris Cardiovascular Research Center, Paris, France.
Jean-Marie DangouWorld Health Organization Regional Office for Africa, Brazzaville, Congo.
Farshad FarzadfarDepartment of Noncommunicable Disease, World Health Organization Headquarters, Geneva, Switzerland.
Jean-Philippe EmpanaUniversité Paris Cité, Inserm, Department of Epidemiology, Paris Cardiovascular Research Center, Paris, France.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Importance: The distribution and determinants of cardiovascular health (CVH) in the World Health Organization (WHO) African Region have been limited to single-country studies. Objective: To estimate the distribution and determinants of CVH score in the WHO African Region, which comprises Algeria and countries in Sub-Saharan Africa. The secondary objective was to estimate time trends in CVH over 20 years. Design, Setting, and Participants: This study constituted repeated nationwide and subnational cross-sectional WHO STEPS (STEPwise Approach to Noncommunicable Disease Risk Factor Surveillance) surveys from 2003 to 2022 in 22 countries in the WHO African Region. Participants included nonpregnant adults aged 18 to 69 years without known cardiovascular disease (CVD). Exposures: Individual factors (age, sex, education level, and marital status) and contextual data from the United Nations Development Programme and the World Bank databases. Main Outcomes and Measures: The primary outcome was the weighted prevalence of the Life's Simple 7 score categories (0-7, 8-11, and 12-14 indicating poor, intermediate, and ideal CVH, respectively) and the factors associated with CVH status. Results: The study population included 73 024 individuals free of CVD (mean [SD] age, 35.4 [12.9] years; 49 505 female [weighted, 49.4%]) and representing 95 million people across 22 countries and 25 surveys. The weighted prevalence of ideal, intermediate, and poor CVH was 26.2% (95% CI, 25.7%-28.0%), 57.9% (95% CI, 54.8%-59.0%), and 15.9% (95% CI, 15.1%-17.0%), respectively. Older age, female sex, lower education, and heavy alcohol consumption were associated with lower odds of achieving intermediate or ideal CVH scores (females vs males: odds ratio [OR] for intermediate CVH, 0.77; 95% CI, 0.67-0.89; OR for ideal CVH, 0.80; 95% CI, 0.64-0.92; ages 55-69 vs 18-25 years: OR for intermediate CVH, 0.14; 95% CI, 0.10-0.20; OR for ideal CVH, 0.06; 95% CI, 0.04-0.09; no education vs tertiary: OR for ideal CVH, 0.63; 95% CI, 0.43-0.92; heavy episodic drinking vs nondrinking: OR for ideal CVH, 0.51; 95% CI, 0.39-0.67). Country-level contextual factors, particularly higher mean years of schooling (β = 0.24; 95% CI, 0.17-0.32), higher education percentage (β = 0.01; 95% CI, 0-0.02), and higher prevalence of undernourishment (β = 3.14; 95% CI, 0.63-5.65), were associated with higher CVH scores. The spatial-temporal model did not reveal any statistically significant trend in the weighted prevalence of CVH score categories between 2003 and 2022, overall and by sex. Conclusions and Relevance: This situational analysis of cross-sectional WHO STEPS surveys of CVH status region identified actionable factors of the CVH status across 22 countries in the WHO African Region. This information is crucial for guiding policy efforts in CVD prevention in countries of the WHO African Region.

Indexed as

Cardiovascular DiseasesAdolescentAdultAfrica South of the SaharaAgedAlgeriaCross-Sectional StudiesEducational StatusFemaleHumansMaleMiddle AgedPrevalenceRisk FactorsWorld Health OrganizationYoung Adult

Identifiers

PMID40884299
PMCPMC12398769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.